Home › Compare › SHANF vs ABBV
SHANF yields 153.14% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 9
Combined, SHANF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SHANF + ABBV for your $10,000?
Shandong Molong Petroleum Machinery Company Limited engages in the design, research and development, production, and sale of products for the energy equipment industry in the People's Republic of China. The company operates through Pipe Products, Three Kinds of Pumping Units, Petroleum Machinery Parts, Tube Blank, High-End Castings and Forgings, and Others segments. The company's products include API and non API casing products, line pipe products, precision steel pipes, hydraulic prop tubes, fluid pipes, cylinder tubes, and boiler tubes; sucker rods; and valve body, cylinder liners, gate valves, and billet products. Its products are used in petroleum, natural gas, coalbed methane, shale gas, machinery processing, urban pipe network, etc., as well as used in equipment for oil and gas drilling, and wind turbine castings. In addition, the company engages in the research of new materials for energy equipment; production and sale of metal casting and forging; sea water desalination activities; waste heat and gas power generation activities; and manufacture and sale of special equipment. It also exports its energy equipment. Shandong Molong Petroleum Machinery Company Limited was founded in 2001 and is based in Shouguang City, China.
Full SHANF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.